Physician profile
Martina Fee
NPI 1821051475
$2,307.66
in general payments reported to CMS, 2019-2025
23 companies · $611 in 2025
The $611 reported for 2025 was more than what 80% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $393 · 2023: $468 · 2024: $497 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490 · Education: $85.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.93 |
| Education | $85.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $378.99 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $294.41 | 2021-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $237.21 | 2021-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $156.99 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $153.15 | 2022-2025 | Tarpeyo |
| Amgen INC. | $148.67 | 2022-2025 | Tavneos, Aranesp, Parsabiv |
| Aurinia Pharma U.S., INC. | $137.21 | 2022-2025 | Lupkynis |
| Akebia Therapeutics INC | $92.76 | 2021-2025 | Vafseo |
| Ardelyx, INC. | $92.15 | 2023-2025 | Ibsrela |
| Travere Therapeutics, INC. | $89.16 | 2023-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $86.94 | 2021-2023 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.55 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $66.91 | 2022-2025 | Velphoro |
| Mallinckrodt Hospital Products INC. | $60.35 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $47.20 | 2021-2023 | Ultomiris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $45.64 | 2024-2025 | Liberty Select Cycler, Nxstage System One |
| Novartis Pharmaceuticals Corporation | $28.63 | 2025 | |
| Apellis Pharmaceuticals, INC. | $26.38 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $20.90 | 2023 | |
| Pharmacosmos Therapeutics INC. | $20.01 | 2021 | |
| Novo Nordisk INC | $19.31 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $17.29 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martina Fee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.